Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

JAK inhibitors and infections risk: focus on herpes zoster
Flavia Sunzini, Iain B. McInnes, Stefan Siebert
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
April W. Armstrong, Melinda Gooderham, Richard B. Warren, et al.
Journal of the American Academy of Dermatology (2022) Vol. 88, Iss. 1, pp. 29-39
Closed Access | Times Cited: 228
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Bruce Strober, Diamant Thaçi, Howard Sofen, et al.
Journal of the American Academy of Dermatology (2022) Vol. 88, Iss. 1, pp. 40-51
Open Access | Times Cited: 185
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
Gerd R Burmester, Stanley Cohen, Kevin Winthrop, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002735-e002735
Open Access | Times Cited: 126
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis
Lawrence F. Eichenfield, Carsten Flohr, Robert Sidbury, et al.
JAMA Dermatology (2021) Vol. 157, Iss. 10, pp. 1165-1165
Open Access | Times Cited: 122
Protein kinases: drug targets for immunological disorders
Leslie Castelo‐Soccio, Hanna Kim, Massimo Gadina, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 787-806
Open Access | Times Cited: 57
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 299-314
Open Access | Times Cited: 20
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 5, pp. 693-707
Open Access | Times Cited: 102
JAK-STAT Pathway: A Novel Target to Tackle Viral Infections
Ifeanyi Jude Ezeonwumelu, Edurne García-Vidal, Ester Ballana
Viruses (2021) Vol. 13, Iss. 12, pp. 2379-2379
Open Access | Times Cited: 70
Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study
Matthew J. Koster, Cynthia S. Crowson, Rachel Giblon, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 6, pp. 861-867
Open Access | Times Cited: 66
Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
Imke Redeker, Katinka Albrecht, Joern Kekow, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 1, pp. 41-47
Open Access | Times Cited: 65
Cellular senescence and the skeleton: pathophysiology and therapeutic implications
Sundeep Khosla, Joshua N. Farr, David G. Monroe
Journal of Clinical Investigation (2022) Vol. 132, Iss. 3
Open Access | Times Cited: 57
Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Hassiel Aurelio Ramírez-Marín, Antonellá Tosti
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 363-374
Open Access | Times Cited: 48
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
El‐Bdaoui Haddad, Sonya Cyr, Kazuhiko Arima, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 7, pp. 1501-1533
Open Access | Times Cited: 47
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
Emma Guttman‐Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 1, pp. 172-181
Open Access | Times Cited: 40
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
Linda Stein Gold, Diamant Thaçi, Jacob P. Thyssen, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 4, pp. 595-607
Open Access | Times Cited: 33
Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis
Qingling Xu, Liyuan He, Yufeng Yin
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 32
VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management
Matthew J. Koster, Terra L. Lasho, Horatiu Olteanu, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 2, pp. 284-299
Closed Access | Times Cited: 32
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
Andrew Blauvelt, Barry Ladizinski, Vimal H. Prajapati, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 3, pp. 478-485
Open Access | Times Cited: 27
Infection risk with JAK inhibitors in dermatoses: a meta‐analysis
Patrick A. Ireland, Matthew J Verheyden, Nicholas Jansson, et al.
International Journal of Dermatology (2024)
Open Access | Times Cited: 10
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure
Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 639-654
Open Access | Times Cited: 9
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO‐1, PSO‐4, and LTE trials
Akimichi Morita, Shinichi Imafuku, Yayoi Tada, et al.
The Journal of Dermatology (2025)
Open Access | Times Cited: 1
JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
R. A. Moura, João Eurico Fonseca
Frontiers in Medicine (2021) Vol. 7
Open Access | Times Cited: 50
Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
Hermine I. Brunner, Jonathan Akikusa, Eslam Al‐Abadi, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225094
Open Access | Times Cited: 7
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
Arthur Kavanaugh, René Westhovens, Kevin Winthrop, et al.
The Journal of Rheumatology (2021) Vol. 48, Iss. 8, pp. 1230-1238
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top